FDA approves Dupixent for chronic obstructive pulmonary disease
The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for ...
Renal & Urology News7h
Extrafine Single Inhaler Triple Therapy Is Effective in Patients With COPD
Extrafine single inhaler triple therapy is effective among patients with COPD who were previously treated with multiple-inhaler triple therapy.
Medscape2d
FDA Approves Dupilumab as Add-On for COPD
The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic Obstructive Pulmonary Disease Treatment
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved ...
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...
framinghamsource2d
New Pulmonary Rehabilitation Program at MetroWest Medical Center is a Breath of Fresh Air for Those with Chronic Lung Disease
For people in the MetroWest region living with lung diseases such as chronic obstructive pulmonary disease (COPD), emphysema, ...
Global Chronic Disease Management Market Size to Reach USD 17.28 Billion by 2033 | Witnessing a CAGR of 12.80%
The global chronic disease management market size is estimated to be worth USD 5.57 billion in 2024 and is projected to reach ...
The American Journal of Managed Care6d
FDA Approves Dupilumab as First Biologic Treatment for COPD
The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...
Too Old to Operate2d
VRE Faecium Pneumonia Following Aspiration in a Patient with COPD
The following is a summary of “Vancomycin-resistant Enterococcus (VRE) Pneumonia in a Patient With Advanced Chronic ...
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
Shares of Regeneron Pharmaceuticals and Sanofi edged higher Friday after their drug to treat chronic obstructive pulmonary ...
The American Journal of Managed Care6h
CHEST Ships Up to Boston for 90th Annual Meeting
The CHEST Annual Meeting 2024 will take place in Boston, Massachusetts, from October 6 to 9, where experts will discuss ...
Medscape1d
Cilomilast: Orally Active Selective Phosphodiesterase-4 Inhibitor for Treatment of Chronic Obstructive Pulmonary Disease
and airway remodeling associated with chronic obstructive pulmonary disease (COPD). Selective PDE4 inhibition is proposed to maximize the antiinflammatory effects of PDE inhibition while ...